Life Science Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global life science products market is experiencing substantial growth, driven by the increased adoption of novel technologies and substantial investments in life science research. According to Fairfield Market Research, market is estimated to be valued at US$ 4.2 bn in 2024 and is expected to reach US$ 6.1 bn by 2031.
Latin America Emerges as a Key Player
In Latin America, the life science products market is undergoing remarkable transformations. Key highlights of the region's market include:
• Brazil is positioned to dominate the market, holding the largest share by 2031, and exhibiting steady growth over the forecast period.
• Mexico is expected to show strong growth, reaching a substantial valuation by 2031.
• Argentina is projected to be the fastest-growing market, with a promising outlook.
• The Rest of Latin America is set to experience consistent growth, becoming a significant player in the market by 2031.
Product Dominance and Research Drive
By product type, the antibodies segment has been dominant in terms of revenue and is expected to maintain its lead throughout the forecast period. Similarly, the basic research segment has led in terms of revenue within the Latin America life science products market and is projected to remain the most attractive segment by application. Additionally, academic research institutes have been the major end users and are expected to continue leading in terms of revenue, recording a market attractiveness index of 2.7 during the forecast period.
Government Initiatives Propel Growth
Several government initiatives across Latin America are boosting life science research, including investments by biopharmaceutical companies in the establishment of manufacturing plants for therapeutic products.
The Future Unfolds in Asia Pacific
The future of the global life science products market is focused on the fast-growing Asia Pacific region. Analysts at Fairfield Market Research have observed a significant shift in investments in research and development, especially in the life sciences domain, from North America and Europe to Asia Pacific. Developing economies like India offer skilled labor and qualified manpower at affordable costs, increasing the scope for outsourcing biotech projects. Furthermore, governments in the Asia Pacific region are actively supporting the growth of the domestic biotechnology industry through tax exemptions on research and development initiatives, increased budgets, public-private partnerships, and attracting foreign direct investments.
In recent years, Taiwan's collaboration with China in clinical trials has attracted numerous companies to invest in these regions. Japan's adoption of the fifth Science and Technology Basic Plan and continued government funding for scientific research further contribute to the region's potential for growth.
The global life science products market is segmented as follows:
by Product Type
• Recombinant Proteins
Immune Checkpoint Regulators
Chemokines
Growth Factors
Cytokines
Colony Stimulating Factors
Hormones
Enzymes and Inhibitors
Others
• Cell Lines
Immunotherapy Cell Lines
Ion Channel Cell Lines
GPCR Cell Lines
Cell Signaling Pathway Cell Lines
Gene Knockout Cell Lines
Cancer Cell Lines
Others
• Antibodies
Immune Checkpoint Antibodies
Epitope Tag Antibodies
Isotype Control Antibodies
Primary Antibodies
Assay Antibodies
Others
• Viable Tumor Samples
• Tumor Tissue Microarrays
by Application
• Drug Discovery and Development
• Basic Research
• Toxicity Screening
• Biopharmaceutical Production
• Drug Screening
• Tissue Engineering
• Forensic Testing
by End User
• Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Forensic Science Laboratories
• Food & Beverage Companies
• Diagnostic Centers
• Others
by Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.
- 1. Executive Summary
- 1.1. Global Life Science Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2023
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Life Science Market Outlook, 2018 – 2031
- 3.1. Global Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
- 3.1.1. Key Highlights
- 3.1.1.1. Recombinant Proteins
- 3.1.1.1.1. Immune Checkpoint Regulators
- 3.1.1.1.2. Chemokines
- 3.1.1.1.3. Growth Factors
- 3.1.1.1.4. Cytokines
- 3.1.1.1.5. Colony Stimulating Factors
- 3.1.1.1.6. Hormones
- 3.1.1.1.7. Enzymes and Inhibitors
- 3.1.1.1.8. Others
- 3.1.1.2. Cell Lines
- 3.1.1.2.1. Immunotherapy Cell Lines
- 3.1.1.2.2. Ion Channel Cell Lines
- 3.1.1.2.3. GPCR Cell Lines
- 3.1.1.2.4. Cell Signaling Pathway Cell Lines
- 3.1.1.2.5. Gene Knockout Cell Lines
- 3.1.1.2.6. Cancer Cell Lines
- 3.1.1.2.7. Others
- 3.1.1.3. Antibodies
- 3.1.1.3.1. Immune Checkpoint Antibodies
- 3.1.1.3.2. Epitope Tag Antibodies
- 3.1.1.3.3. Isotype Control Antibodies
- 3.1.1.3.4. Primary Antibodies
- 3.1.1.3.5. Assay Antibodies
- 3.1.1.3.6. Others
- 3.1.1.4. Viable Tumor Samples
- 3.1.1.5. Tumor Tissue Microarrays
- 3.2. Global Life Science Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 3.2.1. Key Highlights
- 3.2.1.1. Drug Discovery and Development
- 3.2.1.2. Basic Research
- 3.2.1.3. Toxicity Screening
- 3.2.1.4. Biopharmaceutical Production
- 3.2.1.5. Drug Screening
- 3.2.1.6. Tissue Engineering
- 3.2.1.7. Forensic Testing
- 3.3. Global Life Science Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
- 3.3.1. Key Highlights
- 3.3.1.1. Biopharmaceutical Companies
- 3.3.1.2. Contract Research Organizations (CROs)
- 3.3.1.3. Academic & Research Institutes
- 3.3.1.4. Forensic Science Laboratories
- 3.3.1.5. Food & Beverage Companies
- 3.3.1.6. Diagnostic Centers
- 3.3.1.7. Others
- 3.4. Global Life Science Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
- 3.4.1. Key Highlights
- 3.4.1.1. North America
- 3.4.1.2. Europe
- 3.4.1.3. Asia Pacific
- 3.4.1.4. Latin America
- 3.4.1.5. Middle East & Africa
- 4. North America Life Science Market Outlook, 2018 – 2031
- 4.1. North America Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
- 4.1.1. Key Highlights
- 4.1.1.1. Recombinant Proteins
- 4.1.1.1.1. Immune Checkpoint Regulators
- 4.1.1.1.2. Chemokines
- 4.1.1.1.3. Growth Factors
- 4.1.1.1.4. Cytokines
- 4.1.1.1.5. Colony Stimulating Factors
- 4.1.1.1.6. Hormones
- 4.1.1.1.7. Enzymes and Inhibitors
- 4.1.1.1.8. Others
- 4.1.1.2. Cell Lines
- 4.1.1.2.1. Immunotherapy Cell Lines
- 4.1.1.2.2. Ion Channel Cell Lines
- 4.1.1.2.3. GPCR Cell Lines
- 4.1.1.2.4. Cell Signaling Pathway Cell Lines
- 4.1.1.2.5. Gene Knockout Cell Lines
- 4.1.1.2.6. Cancer Cell Lines
- 4.1.1.2.7. Others
- 4.1.1.3. Antibodies
- 4.1.1.3.1. Immune Checkpoint Antibodies
- 4.1.1.3.2. Epitope Tag Antibodies
- 4.1.1.3.3. Isotype Control Antibodies
- 4.1.1.3.4. Primary Antibodies
- 4.1.1.3.5. Assay Antibodies
- 4.1.1.3.6. Others
- 4.1.1.4. Viable Tumor Samples
- 4.1.1.5. Tumor Tissue Microarrays
- 4.2. North America Life Science Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 4.2.1. Key Highlights
- 4.2.1.1. Drug Discovery and Development
- 4.2.1.2. Basic Research
- 4.2.1.3. Toxicity Screening
- 4.2.1.4. Biopharmaceutical Production
- 4.2.1.5. Drug Screening
- 4.2.1.6. Tissue Engineering
- 4.2.1.7. Forensic Testing
- 4.3. North America Life Science Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
- 4.3.1. Key Highlights
- 4.3.1.1. Biopharmaceutical Companies
- 4.3.1.2. Contract Research Organizations (CROs)
- 4.3.1.3. Academic & Research Institutes
- 4.3.1.4. Forensic Science Laboratories
- 4.3.1.5. Food & Beverage Companies
- 4.3.1.6. Diagnostic Centers
- 4.3.1.7. Others
- 4.4. North America Life Science Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 4.4.1. Key Highlights
- 4.4.1.1. U.S. Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 4.4.1.2. U.S. Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 4.4.1.3. U.S. Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 4.4.1.4. Canada Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 4.4.1.5. Canada Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 4.4.1.6. Canada Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Life Science Market Outlook, 2018 – 2031
- 5.1. Europe Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
- 5.1.1. Key Highlights
- 5.1.1.1. Recombinant Proteins
- 5.1.1.1.1. Immune Checkpoint Regulators
- 5.1.1.1.2. Chemokines
- 5.1.1.1.3. Growth Factors
- 5.1.1.1.4. Cytokines
- 5.1.1.1.5. Colony Stimulating Factors
- 5.1.1.1.6. Hormones
- 5.1.1.1.7. Enzymes and Inhibitors
- 5.1.1.1.8. Others
- 5.1.1.2. Cell Lines
- 5.1.1.2.1. Immunotherapy Cell Lines
- 5.1.1.2.2. Ion Channel Cell Lines
- 5.1.1.2.3. GPCR Cell Lines
- 5.1.1.2.4. Cell Signaling Pathway Cell Lines
- 5.1.1.2.5. Gene Knockout Cell Lines
- 5.1.1.2.6. Cancer Cell Lines
- 5.1.1.2.7. Others
- 5.1.1.3. Antibodies
- 5.1.1.3.1. Immune Checkpoint Antibodies
- 5.1.1.3.2. Epitope Tag Antibodies
- 5.1.1.3.3. Isotype Control Antibodies
- 5.1.1.3.4. Primary Antibodies
- 5.1.1.3.5. Assay Antibodies
- 5.1.1.3.6. Others
- 5.1.1.4. Viable Tumor Samples
- 5.1.1.5. Tumor Tissue Microarrays
- 5.2. Europe Life Science Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 5.2.1. Key Highlights
- 5.2.1.1. Drug Discovery and Development
- 5.2.1.2. Basic Research
- 5.2.1.3. Toxicity Screening
- 5.2.1.4. Biopharmaceutical Production
- 5.2.1.5. Drug Screening
- 5.2.1.6. Tissue Engineering
- 5.2.1.7. Forensic Testing
- 5.3. Europe Life Science Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
- 5.3.1. Key Highlights
- 5.3.1.1. Biopharmaceutical Companies
- 5.3.1.2. Contract Research Organizations (CROs)
- 5.3.1.3. Academic & Research Institutes
- 5.3.1.4. Forensic Science Laboratories
- 5.3.1.5. Food & Beverage Companies
- 5.3.1.6. Diagnostic Centers
- 5.3.1.7. Others
- 5.4. Europe Life Science Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 5.4.1. Key Highlights
- 5.4.1.1. Germany Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 5.4.1.2. Germany Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.3. Germany Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 5.4.1.4. U.K. Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 5.4.1.5. U.K. Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.6. U.K. Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 5.4.1.7. France Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 5.4.1.8. France Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.9. France Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 5.4.1.10. Italy Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 5.4.1.11. Italy Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.12. Italy Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 5.4.1.13. Turkey Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 5.4.1.14. Turkey Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.15. Turkey Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 5.4.1.16. Russia Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 5.4.1.17. Russia Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.18. Russia Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 5.4.1.19. Rest of Europe Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 5.4.1.20. Rest of Europe Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 5.4.1.21. Rest of Europe Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Life Science Market Outlook, 2018 – 2031
- 6.1. Asia Pacific Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
- 6.1.1. Key Highlights
- 6.1.1.1. Recombinant Proteins
- 6.1.1.1.1. Immune Checkpoint Regulators
- 6.1.1.1.2. Chemokines
- 6.1.1.1.3. Growth Factors
- 6.1.1.1.4. Cytokines
- 6.1.1.1.5. Colony Stimulating Factors
- 6.1.1.1.6. Hormones
- 6.1.1.1.7. Enzymes and Inhibitors
- 6.1.1.1.8. Others
- 6.1.1.2. Cell Lines
- 6.1.1.2.1. Immunotherapy Cell Lines
- 6.1.1.2.2. Ion Channel Cell Lines
- 6.1.1.2.3. GPCR Cell Lines
- 6.1.1.2.4. Cell Signaling Pathway Cell Lines
- 6.1.1.2.5. Gene Knockout Cell Lines
- 6.1.1.2.6. Cancer Cell Lines
- 6.1.1.2.7. Others
- 6.1.1.3. Antibodies
- 6.1.1.3.1. Immune Checkpoint Antibodies
- 6.1.1.3.2. Epitope Tag Antibodies
- 6.1.1.3.3. Isotype Control Antibodies
- 6.1.1.3.4. Primary Antibodies
- 6.1.1.3.5. Assay Antibodies
- 6.1.1.3.6. Others
- 6.1.1.4. Viable Tumor Samples
- 6.1.1.5. Tumor Tissue Microarrays
- 6.2. Asia Pacific Life Science Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 6.2.1. Key Highlights
- 6.2.1.1. Drug Discovery and Development
- 6.2.1.2. Basic Research
- 6.2.1.3. Toxicity Screening
- 6.2.1.4. Biopharmaceutical Production
- 6.2.1.5. Drug Screening
- 6.2.1.6. Tissue Engineering
- 6.2.1.7. Forensic Testing
- 6.3. Asia Pacific Life Science Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
- 6.3.1. Key Highlights
- 6.3.1.1. Biopharmaceutical Companies
- 6.3.1.2. Contract Research Organizations (CROs)
- 6.3.1.3. Academic & Research Institutes
- 6.3.1.4. Forensic Science Laboratories
- 6.3.1.5. Food & Beverage Companies
- 6.3.1.6. Diagnostic Centers
- 6.3.1.7. Others
- 6.4. Asia Pacific Life Science Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 6.4.1. Key Highlights
- 6.4.1.1. China Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 6.4.1.2. China Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.3. China Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 6.4.1.4. Japan Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 6.4.1.5. Japan Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.6. Japan Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 6.4.1.7. South Korea Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 6.4.1.8. South Korea Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.9. South Korea Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 6.4.1.10. India Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 6.4.1.11. India Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.12. India Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 6.4.1.13. Southeast Asia Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 6.4.1.14. Southeast Asia Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.15. Southeast Asia Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 6.4.1.16. Rest of Asia Pacific Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 6.4.1.17. Rest of Asia Pacific Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 6.4.1.18. Rest of Asia Pacific Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Life Science Market Outlook, 2018 – 2031
- 7.1. Latin America Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
- 7.1.1. Key Highlights
- 7.1.1.1. Recombinant Proteins
- 7.1.1.1.1. Immune Checkpoint Regulators
- 7.1.1.1.2. Chemokines
- 7.1.1.1.3. Growth Factors
- 7.1.1.1.4. Cytokines
- 7.1.1.1.5. Colony Stimulating Factors
- 7.1.1.1.6. Hormones
- 7.1.1.1.7. Enzymes and Inhibitors
- 7.1.1.1.8. Others
- 7.1.1.2. Cell Lines
- 7.1.1.2.1. Immunotherapy Cell Lines
- 7.1.1.2.2. Ion Channel Cell Lines
- 7.1.1.2.3. GPCR Cell Lines
- 7.1.1.2.4. Cell Signaling Pathway Cell Lines
- 7.1.1.2.5. Gene Knockout Cell Lines
- 7.1.1.2.6. Cancer Cell Lines
- 7.1.1.2.7. Others
- 7.1.1.3. Antibodies
- 7.1.1.3.1. Immune Checkpoint Antibodies
- 7.1.1.3.2. Epitope Tag Antibodies
- 7.1.1.3.3. Isotype Control Antibodies
- 7.1.1.3.4. Primary Antibodies
- 7.1.1.3.5. Assay Antibodies
- 7.1.1.3.6. Others
- 7.1.1.4. Viable Tumor Samples
- 7.1.1.5. Tumor Tissue Microarrays
- 7.2. Latin America Life Science Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 7.2.1. Key Highlights
- 7.2.1.1. Drug Discovery and Development
- 7.2.1.2. Basic Research
- 7.2.1.3. Toxicity Screening
- 7.2.1.4. Biopharmaceutical Production
- 7.2.1.5. Drug Screening
- 7.2.1.6. Tissue Engineering
- 7.2.1.7. Forensic Testing
- 7.3. Latin America Life Science Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
- 7.3.1. Key Highlights
- 7.3.1.1. Biopharmaceutical Companies
- 7.3.1.2. Contract Research Organizations (CROs)
- 7.3.1.3. Academic & Research Institutes
- 7.3.1.4. Forensic Science Laboratories
- 7.3.1.5. Food & Beverage Companies
- 7.3.1.6. Diagnostic Centers
- 7.3.1.7. Others
- 7.4. Latin America Life Science Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 7.4.1. Key Highlights
- 7.4.1.1. Brazil Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 7.4.1.2. Brazil Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 7.4.1.3. Brazil Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 7.4.1.4. Mexico Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 7.4.1.5. Mexico Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 7.4.1.6. Mexico Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 7.4.1.7. Argentina Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 7.4.1.8. Argentina Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 7.4.1.9. Argentina Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 7.4.1.10. Rest of Latin America Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 7.4.1.11. Rest of Latin America Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 7.4.1.12. Rest of Latin America Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Life Science Market Outlook, 2018 – 2031
- 8.1. Middle East & Africa Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
- 8.1.1. Key Highlights
- 8.1.1.1. Recombinant Proteins
- 8.1.1.1.1. Immune Checkpoint Regulators
- 8.1.1.1.2. Chemokines
- 8.1.1.1.3. Growth Factors
- 8.1.1.1.4. Cytokines
- 8.1.1.1.5. Colony Stimulating Factors
- 8.1.1.1.6. Hormones
- 8.1.1.1.7. Enzymes and Inhibitors
- 8.1.1.1.8. Others
- 8.1.1.2. Cell Lines
- 8.1.1.2.1. Immunotherapy Cell Lines
- 8.1.1.2.2. Ion Channel Cell Lines
- 8.1.1.2.3. GPCR Cell Lines
- 8.1.1.2.4. Cell Signaling Pathway Cell Lines
- 8.1.1.2.5. Gene Knockout Cell Lines
- 8.1.1.2.6. Cancer Cell Lines
- 8.1.1.2.7. Others
- 8.1.1.3. Antibodies
- 8.1.1.3.1. Immune Checkpoint Antibodies
- 8.1.1.3.2. Epitope Tag Antibodies
- 8.1.1.3.3. Isotype Control Antibodies
- 8.1.1.3.4. Primary Antibodies
- 8.1.1.3.5. Assay Antibodies
- 8.1.1.3.6. Others
- 8.1.1.4. Viable Tumor Samples
- 8.1.1.5. Tumor Tissue Microarrays
- 8.2. Middle East & Africa Life Science Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
- 8.2.1. Key Highlights
- 8.2.1.1. Drug Discovery and Development
- 8.2.1.2. Basic Research
- 8.2.1.3. Toxicity Screening
- 8.2.1.4. Biopharmaceutical Production
- 8.2.1.5. Drug Screening
- 8.2.1.6. Tissue Engineering
- 8.2.1.7. Forensic Testing
- 8.3. Middle East & Africa Life Science Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
- 8.3.1. Key Highlights
- 8.3.1.1. Biopharmaceutical Companies
- 8.3.1.2. Contract Research Organizations (CROs)
- 8.3.1.3. Academic & Research Institutes
- 8.3.1.4. Forensic Science Laboratories
- 8.3.1.5. Food & Beverage Companies
- 8.3.1.6. Diagnostic Centers
- 8.3.1.7. Others
- 8.4. Middle East & Africa Life Science Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 8.4.1. Key Highlights
- 8.4.1.1. GCC Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 8.4.1.2. GCC Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 8.4.1.3. GCC Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 8.4.1.4. South Africa Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 8.4.1.5. South Africa Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 8.4.1.6. South Africa Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 8.4.1.7. Egypt Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 8.4.1.8. Egypt Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 8.4.1.9. Egypt Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 8.4.1.10. Nigeria Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 8.4.1.11. Nigeria Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 8.4.1.12. Nigeria Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 8.4.1.13. Rest of Middle East & Africa Life Science Market by Product Type, Value (US$ Bn), 2018 – 2031
- 8.4.1.14. Rest of Middle East & Africa Life Science Market by Application, Value (US$ Bn), 2018 – 2031
- 8.4.1.15. Rest of Middle East & Africa Life Science Market End User, Value (US$ Bn), 2018 – 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. Product Type vs End User Heatmap
- 9.2. Manufacturer vs End User Heatmap
- 9.3. Company Market Share Analysis, 2023
- 9.4. Competitive Dashboard
- 9.5. Company Profiles
- 9.5.1. Abcam Plc
- 9.5.1.1. Company Overview
- 9.5.1.2. Product Type Portfolio
- 9.5.1.3. Financial Overview
- 9.5.1.4. Business Strategies and Development
- 9.5.2. A.M.S. Biotechnology (Europe) Limited
- 9.5.2.1. Company Overview
- 9.5.2.2. Product Type Portfolio
- 9.5.2.3. Financial Overview
- 9.5.2.4. Business Strategies and Development
- 9.5.3. Bio-Rad Laboratories Inc.
- 9.5.3.1. Company Overview
- 9.5.3.2. Product Type Portfolio
- 9.5.3.3. Financial Overview
- 9.5.3.4. Business Strategies and Development
- 9.5.4. BPS Bioscience Inc.
- 9.5.4.1. Company Overview
- 9.5.4.2. Product Type Portfolio
- 9.5.4.3. Financial Overview
- 9.5.4.4. Business Strategies and Development
- 9.5.5. Crown Bioscience Inc.
- 9.5.5.1. Company Overview
- 9.5.5.2. Product Type Portfolio
- 9.5.5.3. Financial Overview
- 9.5.5.4. Business Strategies and Development
- 9.5.6. Genscript Biotech Corporation
- 9.5.6.1. Company Overview
- 9.5.6.2. Product Type Portfolio
- 9.5.6.3. Financial Overview
- 9.5.6.4. Business Strategies and Development
- 9.5.7. Merck Millipore Limited
- 9.5.7.1. Company Overview
- 9.5.7.2. Product Type Portfolio
- 9.5.7.3. Financial Overview
- 9.5.7.4. Business Strategies and Development
- 9.5.8. PerkinElmer Inc.
- 9.5.8.1. Company Overview
- 9.5.8.2. Product Type Portfolio
- 9.5.8.3. Financial Overview
- 9.5.8.4. Business Strategies and Development
- 9.5.9. Sigma Aldrich Corp.
- 9.5.9.1. Company Overview
- 9.5.9.2. Product Type Portfolio
- 9.5.9.3. Financial Overview
- 9.5.9.4. Business Strategies and Development
- 9.5.10. Thermo Fisher Scientific Inc.
- 9.5.10.1. Company Overview
- 9.5.10.2. Product Type Portfolio
- 9.5.10.3. Financial Overview
- 9.5.10.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook